Washington’s approval of limited home grow changes more than personal cultivation rights. It reshapes enforcement priorities, consumer behavior, and the fairness narrative between individuals and licensed operators.

Congress’s latest budget deal would restrict hemp-derived THC products while removing provisions allowing VA doctors to recommend medical marijuana. The move tightens federal hemp oversight and highlights how cannabis reform momentum is slowing at the national level.

Pennsylvania lawmakers advanced a bill to create a Cannabis Control Board that would oversee both medical marijuana and hemp-derived products. The move emphasizes regulatory reform and consumer safety, not adult-use legalization — but it could set the stage for a more unified and professional cannabis framework.

San Francisco’s first cannabis equity dispensary was meant to symbolize fairness but instead ended in failure. Reports of City Hall insiders profiting highlight how equity programs can fall short, raising hard lessons for operators and investors alike.

Cannabis stocks rallied sharply after Donald Trump suggested Medicare could cover CBD in senior healthcare. While no policy has changed, the surge proves how political commentary still drives cannabis markets. Here’s what operators and investors can learn from this moment.